On Tuesday, Shares of 58.com Inc (ADR)(NYSE:WUBA), subtract -2.80% and closed at $41.91 in the last trading session. The last trading range of the stock ranges between $41.90 and $42.92. 58.com Inc. (WUBA) (“58.com” or the “Company”), China’s leading online marketplace serving local merchants and consumers, recently declared that it plans to release its unaudited financial results for the third quarter ended September 30, 2016 before the open of U.S. markets on Thursday November 10, 2016.
58.com’s administration will host an earnings conference call on Thursday, November 10 2016 at 8:00 a.m. U.S. Eastern Time (9:00 p.m. Beijing / Hong Kong time on the same day).
Insys Therapeutics Inc (NASDAQ:INSY), dropped -2.00% and closed at $11.75 in the last trading session. The last trading range of the stock ranges between $11.54 and $12.72. The company’s Market capitalization is $945.85 Billion with the total Outstanding Shares of 71.77 million. Insys Therapeutics, Inc. (INSY) (“Insys” or “the Company”) recently declared financial results for the three-month period ended September 30, 2016.
Highlights of and subsequent to the third quarter of 2016 include:
Total net revenue was $55.2 million, contrast to $91.3 million for the third quarter of 2015;
Net income totaled $190,000, or $0.00 per basic and $0.00 per diluted share, contrast to net income of $26.1 million, or $0.36 per basic and $0.34 per diluted share, for the third quarter of 2015;
Cash, cash equivalents and investments were $217.2 million as of September 30, 2016; and
Insys received FDA approval for the marketing of SyndrosTM (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol.
On the otherhand Biogen Inc (NASDAQ:BIIB), lost -0.01% and closed at $295.60 in the last trading session. The last trading range of the stock ranges between $292.55 and $299.07. During the 52-week trading session the minimum price at which share price traded, registered at $223.02 and reached to max level of $333.65. Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders. It offers TECFIDERA, AVONEX, and PLEGRIDY to treat relapsing forms of multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohns disease; and FAMPYRA to improve walking ability for patients with MS. The company also provides ELOCTATE to treat adults and children with hemophilia A for control of bleeding episodes; ALPROLIX to treat adults and children with hemophilia B for control of bleeding episodes; RITUXAN for treating non-Hodgkin’s lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), in addition to two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with formerly untreated CLL; and FUMADERM to treat plaque psoriasis. The companys products in Phase III development stage comprise ZINBRYTA, a monoclonal antibody for the treatment of relapsing-remitting MS; Aducanumab for Alzheimers disease; and ISIS-SMNRx for spinal muscular atrophy. Its Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Amiselimod for multiple autoimmune indications; BAN2401 and E2609 for Alzheimer’s disease; Raxatrigine for trigeminal neuralgia; rAAV-XLRS for X-linked juvenile retinoschisis; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise Dapirolizumab pegol for systemic lupus erythematosus (SLE); ISIS DMPK for myotonic dystrophy; Anti-BDCA2 for SLE; Anti-alpha-synuclein for Parkinsons disease; and BIIB063 for sjogrens syndrome.